Asthma: Comprehensive Diagnosis and Management
DIAGNOSIS
Asthma diagnosis requires demonstrating episodic symptoms of airflow obstruction PLUS objective evidence of reversible airway obstruction on spirometry, defined as FEV1 increase >200 mL AND ≥12% from baseline after inhaling a short-acting β2-agonist. 1
Key Clinical Symptoms to Identify
Look for these specific symptom patterns:
- Cough (particularly worse at night)
- Recurrent wheeze
- Recurrent difficulty breathing
- Recurrent chest tightness
Critical diagnostic feature: Symptoms must be variable and episodic, not constant 1
Symptom Triggers That Strengthen Diagnosis
Symptoms occur or worsen with:
- Exercise
- Viral infections
- Inhalant allergens (animals with fur/hair, house dust mites, mold, pollen)
- Irritants (tobacco/wood smoke, airborne chemicals)
- Weather changes
- Strong emotional expression (laughing/crying hard)
- Stress
- Menstrual cycles
- Nighttime awakening 1
Essential Diagnostic Testing
Spirometry is mandatory for all patients ≥5 years of age to demonstrate obstruction and assess reversibility 1. Patients' perceptions of airflow obstruction are highly variable, making objective testing essential.
Bronchodilator reversibility test:
- Administer short-acting β2-agonist
- Positive if FEV1 increases >200 mL AND ≥12% from baseline
- Some evidence suggests ≥10% of predicted FEV1 may better separate asthma from COPD 1
When spirometry shows FEV1 ≥70% predicted but suspicion remains:
- Consider bronchial provocation testing 2
- If unavailable, may initiate diagnostic anti-inflammatory therapy if:
- PEF bronchodilation test shows ≥20% increase from baseline, OR
- FEV1 variability ≥12% and ≥200 mL between two tests, OR
- Small airway dysfunction (2 of 3 parameters ≤65% predicted: MEF25, MEF50, MMEF) with FeNO ≥35 ppb 2
Physical Examination Findings
Upper respiratory tract:
- Increased nasal secretion
- Mucosal swelling
- Nasal polyps
Chest:
- Wheezing during normal breathing or prolonged forced exhalation
- Hyperexpansion of thorax
- Use of accessory muscles
- Hunched shoulders
- Chest deformity
Skin:
- Atopic dermatitis
- Eczema
Important caveat: Normal physical examination does NOT rule out asthma due to disease variability between episodes 1
Additional Diagnostic Considerations
Identify allergen sensitivities: Skin-prick tests should be systematically considered, as allergy is frequent in adult asthma and avoiding relevant allergens significantly improves control 3
Key environmental risk factors:
- House dust mite and Alternaria sensitization/exposure (most important)
- Viral respiratory infections (RSV, rhinovirus)
- Tobacco smoke exposure 1
SEVERITY CLASSIFICATION
Assess severity BEFORE initiating therapy to guide initial treatment selection 1
Initial Severity Classification (Treatment-Naive Patients)
Assess two domains: Impairment and Risk
Intermittent Asthma (Step 1):
- Symptoms <2 times/month
- No nocturnal symptoms
- No risk of exacerbations
- FEV1 >80% predicted 2
Mild Persistent (Step 2):
- Symptoms >2 days/week but not daily
Moderate Persistent (Step 3-4):
- Daily symptoms
- Some limitation of activity
Severe Persistent (Step 5-6):
- Continuous symptoms
- Frequent exacerbations
- Extremely limited activity 1
After treatment initiation: Severity is reclassified based on the lowest treatment step required to maintain control 1
GOALS OF THERAPY
Primary goals target two domains: reducing impairment AND reducing risk 1
Reduce Impairment:
- Prevent chronic/troublesome symptoms
- Require infrequent SABA use (≤2 days/week, excluding exercise prevention)
- Maintain near-normal pulmonary function
- Maintain normal activity levels (exercise, work, school attendance)
Reduce Risk:
- Prevent recurrent exacerbations
- Minimize emergency department visits/hospitalizations
- Prevent loss of lung function (prevent reduced lung growth in children)
- Provide optimal pharmacotherapy with minimal adverse effects 1
MANAGEMENT: STEPWISE APPROACH
Inflammation is the primary target of treatment 1. Current evidence strongly supports that all adults, adolescents, children, and most preschoolers with asthma should receive ICS-containing treatment 4. SABA-only treatment is NOT recommended 4.
Step 1: Intermittent Asthma
Preferred: As-needed low-dose ICS-formoterol (anti-inflammatory reliever, AIR-only approach) 4, 2
- Significantly reduces moderate-to-severe exacerbations compared with SABA monotherapy 2
- For budesonide-formoterol: 1-2 inhalations as needed, maximum 8 inhalations/day 2
Step 2: Mild Persistent Asthma
Preferred: As-needed low-dose ICS-formoterol 4, 2
Alternative (not preferred):
- Daily low-dose ICS
- Leukotriene receptor antagonists (LTRAs)
- Cromolyn sodium or nedocromil 1
Step 3: Moderate Persistent Asthma
Preferred for patients ≥5 years:
- Low-dose ICS-LABA combination, OR
- Increase ICS to medium dose 1
ICS-LABA demonstrates synergistic anti-inflammatory and bronchodilator effects, achieving efficacy equivalent to or better than doubling ICS dose 2
Alternative adjunctive therapy:
- LTRAs (not preferred compared to LABA in patients ≥12 years) 1
- Sustained-release theophylline (requires serum monitoring) 1
Step 4: Moderate-Severe Persistent Asthma
Preferred:
- Medium-to-high dose ICS-LABA 1
Consider adding:
- Long-acting muscarinic antagonist (LAMA) - triple therapy
- Triple combination inhalers improve symptoms, lung function, and reduce exacerbations when asthma uncontrolled on medium/high-dose ICS-LABA 2
Step 5-6: Severe Persistent Asthma
Definition of severe asthma: Uncontrolled despite ≥3 months of continuous medium/high-dose ICS-LABA, after treating comorbidities and avoiding environmental triggers, OR worsening when stepping down 2
Management approach:
High-dose ICS-LABA combination
Add biologic therapy for Type 2 asthma:
- Omalizumab (anti-IgE): For patients ≥12 years with allergies requiring step 5-6 care; must have sensitivity to relevant allergens (dust mite, cockroach, cat, dog) 1
- Anti-IL-5 agents (mepolizumab, reslizumab): For eosinophilic phenotype 5
- Anti-IL-5Rα agents: For eosinophilic phenotype 2
- Anti-IL-4Rα agents: For Type 2 inflammation 2
Type 2 inflammation criteria: Elevated blood/sputum eosinophils (≥150/μl), and/or elevated FeNO, and/or atopy/elevated total IgE 2
Low-dose oral corticosteroids (≤7.5 mg/day prednisone equivalent) as LAST resort 2
Consider additional therapies:
Critical safety note: Clinicians administering omalizumab must be prepared and equipped to identify and treat anaphylaxis 1
MEDICATION DETAILS
Long-Term Controller Medications
Inhaled Corticosteroids (ICS):
- Preferred long-term control therapy for all ages 1
- Long-term treatment at recommended clinical doses is safe
- Caution: Prolonged high-dose ICS may cause osteoporosis, hypothalamic-pituitary-adrenal axis suppression, increased pneumonia risk 2
Long-Acting β2-Agonists (LABA):
- Salmeterol and formoterol
- NEVER use as monotherapy - must be combined with ICS 1
- Duration of bronchodilation ≥12 hours
- Preferred adjunctive therapy with ICS in patients ≥12 years 1
- May prevent exercise-induced bronchospasm, but duration doesn't exceed 5 hours with chronic use; frequent use before exercise discouraged as it may mask poor control 1
Leukotriene Modifiers:
- LTRAs (montelukast, zafirlukast): Alternative therapy for step 2 care
- Zileuton (5-lipoxygenase inhibitor): Requires liver function monitoring 1
Anticholinergics:
- Tiotropium (LAMA): Effective controller in moderate-severe asthma 5
Quick-Relief Medications
Short-Acting β2-Agonists (SABA):
- Albuterol, levalbuterol, pirbuterol
- Treatment of choice for acute symptoms and exercise-induced bronchospasm prevention
- Warning sign: Use >2 days/week for symptom relief (not exercise prevention) indicates inadequate control and need for intensified anti-inflammatory therapy
- Regularly scheduled daily chronic use NOT recommended 1
Anticholinergics:
- Ipratropium bromide: Provides additive benefit to SABA in moderate/severe exacerbations in emergency care setting only, NOT hospital setting 1
Systemic Corticosteroids:
- Oral corticosteroids for moderate/severe exacerbations to speed recovery
- Short courses often used to gain prompt control
- Doubling ICS dose for home management is NOT effective 1
MONITORING AND ASSESSMENT
After initiating therapy, emphasis shifts from severity to CONTROL assessment 1
Follow-Up Schedule
- Every 2-6 weeks while gaining control or stepping up therapy 1
- Every 1-6 months once control achieved (interval depends on treatment step) 1
- Every 3 months if stepping down therapy anticipated 1
At Every Visit Assess:
- Asthma control (symptoms, SABA use, activity limitation)
- Medication technique (inhaler technique)
- Written asthma action plan review
- Patient adherence
- Patient concerns 1
Spirometry Monitoring
Obtain spirometry:
- At initial assessment
- After treatment initiated and symptoms/PEF stabilized
- During progressive/prolonged loss of control
- At least every 1-2 years (more frequently if not well controlled) 1
Low FEV1 indicates current obstruction AND risk for future exacerbations 1
Biomarker Monitoring
Fractional Exhaled Nitric Oxide (FeNO):
- Reflects Type 2 airway inflammation
- ≥35 ppb suggests eosinophilic inflammation 2
Peripheral Blood Eosinophils:
- ≥150/μl identifies eosinophilic phenotype/Type 2 inflammation
- Key biomarker to predict and evaluate biologic response 2
Induced Sputum Eosinophils:
- Gold standard for airway inflammation assessment
- Used for phenotype classification, corticosteroid response prediction, exacerbation risk assessment 2
Peak Flow Monitoring
Consider daily peak flow monitoring for:
- Moderate/severe persistent asthma
- History of severe exacerbations
- Patients who poorly perceive airway obstruction 1
COMORBIDITY MANAGEMENT
Identify and treat comorbid conditions that affect asthma control 1:
- Sinusitis
- Rhinitis (allergic and non-allergic)
- Gastroesophageal reflux disease (GERD)
- Obstructive sleep apnea (OSA)
- Obesity
- Stress/depression
- Anxiety
Psychosocial assessment (anxiety/depression scales) should be performed if patients have dyspnea/chest tightness after routine therapy with normalized lung function, eosinophils, and FeNO 2
ENVIRONMENTAL CONTROL
Multifaceted approaches necessary; single interventions generally ineffective 1
Key Strategies:
- Reduce exposure to house dust mites and Alternaria (most important allergens) 1
- Avoid tobacco smoke exposure
- Minimize exposure to identified allergens based on sensitivity testing
- Reduce irritant exposures (wood smoke, airborne chemicals)
Immunotherapy Considerations:
Subcutaneous immunotherapy:
- Consider for patients with allergies requiring step 2-4 care (mild/moderate persistent asthma)
- When clear relationship between symptoms and allergen exposure exists
- Clinicians must be prepared to treat anaphylaxis 1
Sublingual immunotherapy (house dust mite):
- For HDM-sensitized adolescents/adults with FEV1 >70% predicted
- May reduce symptoms and ICS dose if symptoms persist despite low-to-medium dose ICS-containing therapy 2
EXACERBATION MANAGEMENT
Severity Classification
Severe exacerbation: FEV1 or PEF <40% predicted - indicates potential benefit of adjunctive therapies 1
Discharge goal: FEV1 or PEF ≥70% predicted 1
Emergency Treatment
Medications:
- Albuterol (or levalbuterol) - primary bronchodilator 1
- Oxygen 1
- Oral systemic corticosteroids (emphasize oral route) 1
- Anticholinergics (ipratropium) - use in emergency care, NOT hospital care 1
For severe exacerbations unresponsive to initial treatment:
At Discharge:
- Initiate or continue ICS 1
- Provide written asthma action plan
- Schedule follow-up within 2-6 weeks
- Review inhaler technique
- Assess and address factors contributing to exacerbation
PATIENT EDUCATION
Education should occur at ALL points of care: clinic settings, emergency departments, hospitals, pharmacies, schools, community settings, and patients' homes 1
Essential Education Components:
Written Asthma Action Plan (develop in partnership with patient):
- Daily management instructions (long-term control medications, environmental control)
- How to recognize worsening asthma
- How to adjust medications
- When to seek medical care 1
Self-Monitoring:
Medication Technique:
- Correct inhaler technique (use of devices)
- Difference between long-term control and quick-relief medications 1
Environmental Control:
- Avoiding triggers and allergens
Cultural Considerations:
- Tailor education to literacy level
- Appreciate cultural beliefs and practices in asthma management 1
Involve entire healthcare team: physicians, nurses, pharmacists, respiratory therapists, asthma educators 1
RED FLAGS: RISK FACTORS FOR ASTHMA-RELATED DEATH
Immediate specialist referral warranted if ANY of the following present 2:
- History requiring intubation and mechanical ventilation
- Hospitalization or emergency visit for asthma in past year
- Currently using or recently stopped oral corticosteroids
- No current ICS use
- Overuse of SABA (>1 canister salbutamol/month or equivalent)
- Psychiatric illness or psychosocial problems (including sedative use)
- Poor adherence
- Confirmed food allergy history
- Comorbidities: pneumonia, diabetes, arrhythmias
Any patient with ≥2 exacerbations in one year should be referred to pulmonology 6
SPECIAL POPULATIONS AND PHENOTYPES
Cough Variant Asthma (CVA)
- Treatment principles same as typical asthma
- ICS-LABA recommended as first choice, use >8 weeks 2
- For poor response with severe inflammation: consider adding LTRA or short-term oral corticosteroids (10-20 mg/day for 3-5 days) 2
Aspirin-Induced Asthma (AIA)
- Most effective prevention: avoid aspirin 2
- Desensitization therapy may be considered for patients requiring high-dose ICS, failed conventional treatment for nasal inflammation/polyposis, or requiring aspirin for other diseases 2
Asthma with Chronic Rhinosinusitis with Nasal Polyps
- May benefit from anti-IgE, anti-IL-5, anti-IL-5Rα, or anti-IL-4Rα monoclonal antibodies 2
Asthma-COPD Overlap (ACO)
Consider diagnosis if asthma patient has:
- Persistent airflow limitation (FEV1/FVC <70% post-bronchodilator)
- History of noxious gas/substance exposure (smoking ≥10 pack-years)
- Emphysema on high-resolution CT
- Decreased diffusion capacity after 3-6 months standardized treatment 2
Fungal-Sensitized Asthma
- Antifungal drugs can reduce airway inflammation and systemic corticosteroid dose 2
- Biologic therapies (anti-IgE, anti-IL-5, anti-IL-5Rα, anti-IL-4Rα) can reduce exacerbations and improve control 2
CLINICAL REMISSION
Patients achieving ≥1 year of symptom-free status, no exacerbations, normal/near-normal lung function, and no need for oral corticosteroids after biologic or other anti-asthma therapy may be considered to have achieved "clinical remission" 2